687 Companies

Access all companies

Find technology partners quickly.

Spotfolio tracks over one million companies in technology industries.

There are 687 companies in the field of Biopharma on spotfolio that produce or deliver products, that utilize or research technologies or that are otherwise engaged in topics such as Clinical, Drug, Patients, Treatment, Therapeutic, Disease, Pharmaceutical, Dose .

Start-ups (85)

Early-stage companies (188)

Established companies (373)

The majority of these companies is located in the following countries.

United States (383)

United Kingdom (48)

Canada (30)

China (25)

Example Companies

Find companies in your area

Pharma Two B

established

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

stage Parkinson’s Disease (PD). P2B001 is a combination of low dose pramipexole and low dose rasagiline administered as a proprietary sustained release formulation ...

endpoints for both dose combinations. Specifically, the results showed: - Overall improvement of 5.97 UPDRS points for the high dose combination, leading ...

to placebo (P<0.001) - Overall improvement of 5.14 UPDRS points in the low dose combination, leading to a significant change of 3.84 UPDRS units compared ...

early stage Parkinson’s disease, in a sustained release profile. Given as low dose monotherapies, the anti-Parkinsonian effect of these drugs given individually ...

potentially serious side effects. In preclinical studies, we observed that a low dose combination of these two drugs administered in a sustained release formulation

stage Parkinson’s Disease (PD). P2B001 is a combination of low dose pramipexole and low dose rasagiline administered as a proprietary sustained release formulation ...

endpoints for both dose combinations. Specifically, the results showed: - Overall improvement of 5.97 UPDRS points for the high dose combination, leading ...

to placebo (P<0.001) - Overall improvement of 5.14 UPDRS points in the low dose combination, leading to a significant change of 3.84 UPDRS units compared ...

early stage Parkinson’s disease, in a sustained release profile. Given as low dose monotherapies, the anti-Parkinsonian effect of these drugs given individually ...

potentially serious side effects. In preclinical studies, we observed that a low dose combination of these two drugs administered in a sustained release formulation

Engage Therapeutics Engage Therapeutics, Inc.

start-up

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

measured predose, then at 2 min, 10 min, 30 min, 1, 2, 4 and 6 hours post-dose. Plasma concentration of study drug was measured at each time point. Sedation ...

near-maximal effect occurring by 2 minutes post dose. Higher doses produced effects on SPR out to 4 hours. Sedation was dose related, but separated from SPR effects ...

suppresses epileptiform activity within 2 minutes. Duration of effect was dose related, as was sedation. This data supports the possibility that inhaled ...

administered during each of the five visits. Patients Screened In-clinic Dose 2 4 1 5 3 21 days 8 Model used to assess effects of potential AEDs in a ...

Change in Standardized Photosensitivity Range (SPR) in subjects receiving each dose of Staccato Alprazolam Secondary Study Endpoints • Assessment of sedation ...

sedation and somnolence Subject #2 10 Pharmacokinetic Data Demonstrated Dose Proportionality Mean SPR 8 PBO 6 0.5 Alprazolam 1.0 Alprazolam 2.0 Alprazolam

Kuros Biosciences Kuros Biosciences AG

established

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

Study design A Phase 2 randomized, controlled, open-label (dose-blinded), multi-center, dose-finding study of the safety and efficacy of Fibrin-PTH (KUR-111) ...

into the fibrin sealant. The study included PTH in fibrin at high or low dose and compared to autograft alone.5 Primary & secondary endpoints Two hundred ...

fracture union in 96.2% of patients treated with low dose KUR-111, 100% of those treated with high dose KUR-111 and 98.2% of those treated with autograft

fractures Study design A Phase 2 randomized, controlled, open-labeled (dose-blinded) dose finding study of the safety and efficacy of Fibrin-PTH (KUR-113) in ...

the fibrin sealant. The study included PTH in fibrin at high, medium or low dose as an adjunct to standard of care (mechanical fixation) compared to standard ...

83%, and 75% for the low, medium, and high dose groups, respectively. For both analyses, the medium dose group had significantly better healing than the

Collaborative Medicinal Development Collaborative Medicinal Development LLC

early-stage

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

October 2016, CMD initiated a first-in-man (at therapeutic doses) phase 1 dose-finding and pharmacokinetic (PK) study of CuATSM in patients with both sporadic ...

NCT02870634).Dose cohorts (n=6) are evaluated for PK and safety following administration of a single oral doses, followed by a 28-day repeated daily dose safety ...

tolerated, dose escalation will continue until ALS patients show plasma levels equivalent to those seen in mice given 30 mg/kg/day, a dose level that showed ...

three dose cohorts.Based on PK findings for the first four dose cohorts, completed shortly after the MNDA meeting, CMD expects to complete the dose-finding ...

the first two dose cohorts in the ALS study had been completed successfully. The starting dose for the Parkinson’s disease study was a dose that had been ...

well tolerated in the ALS study. In August 2017, CMD initiated a phase 1 dose-finding study of CuATSM in patients with early idiopathic Parkinson’s disease

City Drugs City Drugs NY Corp.

early-stage

Access

  • Technologies
  • Core data such as location, employees, revenues
  • Similar and peer companies
  • and more

Web Quotes

Infusion Supplies: □ YES □ NO Dose: Inject 150mg (two 75 mg injections) subcutaneously □ MD □ atStarting Body Weight of patient Dose Number of vials week 0 & ...

& week 4 QTY: 4 Refills: 0 Less than 60kg 500mg 2 Maintenance Dose: Inject 150mg (two 75 mg injections) subcutaneously 60-100kg 750mg 3 every 12 weeks ...

90mg/ml Prefilled Syringe Dose: Infuse ____mg IV at weeks 0, 2 & 4 QTY:_____ vials □ Initial Starting Dose: □ Maintenance Dose: Infuse ____mg IV every 4 ...

1 and Day 29 QTY: 1 Refills: 1 □ ORENCIA PSORIATIC ARTHRITIS Maintenance Dose: Prefilled syringe: □ 50mg/0.4 ml □ 87.5mg/0.7ml □ 125mg/1mL 45mg subcutaneously ...

subcutaneously every 12 weeks Dose: Inject 125 mg subcutaneously at week 0 QTY: 1 Refills: 0 □ Starting Maintenance Dose: Inject 125 mg subcutaneously ...

PSORIASIS Refills: _______ 80mg/ml □ Prefilled Syringe 80mg/ml □ Autoinjector Dose: Inject 160 mg (2 pens) at Week 0, □ Starting □ OTEZLA followed by 80 mg

PSORIATIC ARTHRITIS Dispense: □ SureClick (prefilled autoinjector) □ PFS □ SDV Dose: Inject 400mg (two 200 mg subcutaneous injections) □ Starting □ Mini (□ ...

400 mg subcutaneously every 4 weeks QTY: 2 Refills: ______ PLAQUE PSORIASIS Dose: Inject 50 mg subcutaneously twice weekly (72-96 hours apart) □ Starter Inject ...

Refills: ______ □ Maint.: Dose: Inject 400mg (two 200 mg subcutaneous injections) □ Starting start maintenance without a loading dose □ May at weeks 0, 2 & ...

__________________________________________________ QTY: ______ Refills: ______ Dose: Inject 300 mg dose (2 Pens) subcutaneously once weekly □ Starting for 5 weeks at weeks ...

weeks 0, 1, 2, 3, and 4 QTY: 8 pens Refills: 0 Maintenance Dose: □ HUMIRA Citrate-Free 300 mg dose (2 Pens) subcutaneously at week 4 then, □ Inject 80mg/0 ...

PSORIATIC ARTHRITIS HIDRADENITIS SUPPURATIVA Dose: Inject 150 mg dose (1 Pen) subcutaneously once weekly □ Starting Dose: Inject 160 mg initially subcutaneously

Use detailed technology terms.

Only spotfolio allows for searching with detailed technology terms, as we provide you with all topics that technology companies talk about.

Companies addressing these topics might be of specific interest to you, as they share more specific, niche topics.

Use Cases

Register now

Why Technology Scouting?

Technology scouting is the basis for your innovation management, identifies new technological developments as early as possible and protects you from disruptive business models.

Identify technology partners

Boost your market research

Look beyond major players

Build long and short lists

Collect technology leaders, providers, start ups and potential new partners in lists via simple tagging to take further steps with your team.